Delamanid

J04AK06(WHO) UK:POM(Prescription only)EU:Rx-onlyIn general: ℞ (Prescription only) (2R)-2-Methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-b][1,3]oxazole 681492-22-8 6480466 DB11637 4981055 8OOT6M1PC7 D09785 CHEBI:134742 ChEMBL218650 DTXSID60218326 Interactive image FC(F)(F)Oc5ccc(OC4CCN(c3ccc(OC[C@@]2(Oc1nc(cn1C2)[N+]([O-])=O)C)cc3)CC4)cc5 InChI=1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1Key:XDAOLTSRNUSPPH-XMMPIXPASA-N Delamanidis sold under the brand nameDeltyba, is a medication used to treattuberculosis.Specifically it is used, along with otherantituberculosis medications, for activemultidrug-resistant tuberculosis.It is takenby mouth. There are common side effects which include headache, dizziness, and nausea.Other side effects includeQT prolongation.Delamanid works by blocking the manufacture ofmycolic acidsthus destabilising the bacterialcell wall.It is in thenitroimidazoleclass of medications. Delamanid was approved for medical use in 2014 in Europe, Japan, and South Korea.It is on theWorld Health Organization's List of Essential Medicines.As of 2016 theStop TB Partnershiphad an agreement to get the medication for US$1,700 per six month for use in more than 100 countries.